5.56
price up icon4.51%   0.24
after-market 시간 외 거래: 5.56
loading
전일 마감가:
$5.32
열려 있는:
$5.34
하루 거래량:
94,850
Relative Volume:
0.39
시가총액:
$314.81M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-4.1493
EPS:
-1.34
순현금흐름:
$-58.82M
1주 성능:
+2.77%
1개월 성능:
+11.20%
6개월 성능:
+49.46%
1년 성능:
+153.88%
1일 변동 폭
Value
$5.25
$5.57
1주일 범위
Value
$5.05
$5.63
52주 변동 폭
Value
$1.96
$6.91

디자인 테라 Stock (DSGN) Company Profile

Name
명칭
Design Therapeutics Inc
Name
전화
858-293-4900
Name
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
Name
직원
57
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
DSGN's Discussions on Twitter

디자인 테라 Stock (DSGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-05-04 업그레이드 Goldman Sell → Neutral
2022-06-10 개시 Wedbush Outperform
2022-05-02 개시 RBC Capital Mkts Outperform
2022-01-19 개시 Goldman Sell
2021-04-20 개시 Goldman Neutral
2021-04-20 개시 Piper Sandler Overweight
2021-04-20 개시 SVB Leerink Outperform
모두보기

디자인 테라 주식(DSGN)의 최신 뉴스

pulisher
09:24 AM

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, - GlobeNewswire

09:24 AM
pulisher
Oct 31, 2024

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI - Yahoo Finance

Oct 31, 2024
pulisher
Oct 30, 2024

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Longview News-Journal

Oct 30, 2024
pulisher
Oct 30, 2024

A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive

Oct 30, 2024
pulisher
Oct 30, 2024

Dr. Beyza Bulutoglu Celebrated for Dedication to the Field of Protein Engineering and Drug Discovery - 24-7 Press Release

Oct 30, 2024
pulisher
Oct 28, 2024

Spinocerebellar Ataxias Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart

Oct 28, 2024
pulisher
Oct 27, 2024

Seaport Therapeutics Secures $225M for New Kind of Depression Drug - MedCity News

Oct 27, 2024
pulisher
Oct 23, 2024

Synthetic Nanoassemblies for Regulating Organelles: From Molecular Design to Precision Therapeutics - ACS Publications

Oct 23, 2024
pulisher
Oct 21, 2024

Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc - Barchart

Oct 21, 2024
pulisher
Oct 18, 2024

Enhancing De Novo Drug Design across Multiple Therapeutic Targets with CVAE Generative Models - ACS Publications

Oct 18, 2024
pulisher
Oct 18, 2024

When (DSGN) Moves Investors should Listen - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 17, 2024

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential - ForexTV.com

Oct 16, 2024
pulisher
Oct 16, 2024

Glycomic Therapeutics Market Innovations, Challenges, - openPR

Oct 16, 2024
pulisher
Oct 15, 2024

Dimensional Fund Advisors LP Has $271,000 Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Oct 15, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Invests $81,000 in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Reduces Holdings in TrueCar, Inc. (NASDAQ:TRUE) - Defense World

Oct 14, 2024
pulisher
Oct 12, 2024

Squarepoint Ops LLC Has $294,000 Stock Holdings in Civeo Co. (NYSE:CVEO) - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Squarepoint Ops LLC Increases Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Squarepoint Ops LLC Lowers Stock Holdings in AerSale Co. (NASDAQ:ASLE) - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder - BioSpace

Oct 11, 2024
pulisher
Oct 10, 2024

Tech News | American Press Technology News - Business Wire

Oct 10, 2024
pulisher
Oct 10, 2024

Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MyChesCo

Oct 10, 2024
pulisher
Oct 09, 2024

Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

Cubist Systematic Strategies LLC Grows Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Oct 08, 2024
pulisher
Oct 04, 2024

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Oct 04, 2024
pulisher
Oct 03, 2024

Point72 Asset Management L.P. Buys 397,285 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Oct 03, 2024
pulisher
Oct 03, 2024

Point72 Asset Management L.P. Has $3.32 Million Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

Point72 Asset Management L.P. Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Oct 03, 2024
pulisher
Sep 30, 2024

Almitas Capital LLC Has $4.20 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Sep 30, 2024
pulisher
Sep 29, 2024

Almitas Capital LLC Purchases 227,180 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Design Therapeutics stockInnovative approach in genetic disorder treatment - Investing.com

Sep 27, 2024
pulisher
Sep 26, 2024

(DSGN) On The My Stocks Page - Stock Traders Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock - Yahoo Finance

Sep 26, 2024
pulisher
Sep 26, 2024

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming - The Bakersfield Californian

Sep 26, 2024
pulisher
Sep 25, 2024

Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online

Sep 25, 2024
pulisher
Sep 25, 2024

Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles - Business Wire

Sep 25, 2024
pulisher
Sep 24, 2024

Halozyme Therapeutics And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency

Sep 24, 2024
pulisher
Sep 24, 2024

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - StockTitan

Sep 24, 2024
pulisher
Sep 23, 2024

How to interpret Design Therapeutics Inc (DSGN)’s stock chart patterns - US Post News

Sep 23, 2024
pulisher
Sep 20, 2024

Friedreich’s Ataxia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024-2034, estimated DelveInsight - Barchart

Sep 20, 2024
pulisher
Sep 20, 2024

Initial in vivo validation of novel cancer therapeutics using AI - Drug Target Review

Sep 20, 2024
pulisher
Sep 19, 2024

Designer brands director sells $145,640 in company stock - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

Progressive Ataxia And Weakness Disorders Market Segments, Drivers, Restraints, And Trends For 2024-2033 - EIN News

Sep 19, 2024
pulisher
Sep 19, 2024

Rocket Pharmaceuticals Maxes Out Recruitment in Pivotal Trial for Danon Disease Gene Therapy RP-A501 - CGTLive™

Sep 19, 2024
pulisher
Sep 18, 2024

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day - Yahoo Finance

Sep 18, 2024
pulisher
Sep 18, 2024

Designer Brands Inc’s latest rating changes from various analysts - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Short Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Decreases By 6.9% - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - StockTitan

Sep 18, 2024

디자인 테라 (DSGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):